End of treatment and 12-month post-treatment outcomes in patients treated with all-oral regimens for rifampicin-resistant tuberculosis in Ukraine: a prospective cohort study.

ABSTRACT: The World Health Organization has called for operational research on all-oral shorter regimens for rifampin-resistant and multidrug-resistant forms of tuberculosis (RR/MDR-TB). We followed a cohort of patients in Zhytomyr, Ukraine for effectiveness, safety, tolerability and feasibility of bedaquiline & delamanid-based treatment regimens under programmatic conditions. This was a single-arm implementation study. All consenting persons with RR/MDR-TB were enrolled between 1 April 2019 and 31 May 2021 and followed up 12-months after treatment completion. We assessed quality of life and depression symptoms between start and end-of-treatment. We enrolled 300 patients. Overall, 212 (71%) patients were cured, 22 (7%) patients completed treatment, median time to culture conversion was 58 days (IQR:

SUBMITTER: Fardhdiani V 

PROVIDER: S-EPMC12101767 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature